Elekta AB (EKTAY)
OTHER OTC:EKTAY
Want to see EKTAY full AI Analyst Report?
EKTAY Stock Chart & Stats
$6.37
-$0.10(-1.78%)
At close: 4:00 PM EST
$6.37
-$0.10(-1.78%)
Day’s Range― - ―
52-Week Range$4.42 - $6.88
Previous CloseN/A
Volume122.00
Average Volume (3M)73.00
Market Cap
$1.87B
Enterprise Value$21.82B
Total Cash (Recent Filing)$3.17B
Total Debt (Recent Filing)$7.30B
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)-1.40
Shares Outstanding368,587,650
10 Day Avg. Volume0
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.92
Price to Sales (P/S)1.26
P/FCF Ratio8.98
Enterprise Value/Market Cap11.65
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit3.52
Enterprise Value/Ebitda11.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationResilient cash conversion despite a reported net loss provides durable financial flexibility. Strong FCF funds service network investment, product upgrades, dividends and de‑leveraging without needing equity raises, cushioning the business through multi‑quarter cycles and supporting long‑term strategic execution.
Product Approvals And Market PositionRegulatory approval and sustained product launches expand addressable market and drive system and upgrade demand over years. Market leadership in China (high‑30s share) and recovering unit demand underpin durable order flow and recurring service revenues from a large installed base.
Structural Cost Savings And Operating Model ProgressA sizable, mostly executed cost program that targets permanent run‑rate savings will sustainably improve margins and operating leverage. Mix of COGS/OpEx savings improves gross and EBIT margins long‑term, bolstering profitability as revenue normalizes and protecting cash flow.
Bears Say
Profitability Deterioration And Net LossA swing to net loss and materially compressed EBIT/EBITDA margins weaken retained earnings and return metrics. This reduces reinvestment capacity for R&D and installs, pressures ROE, and requires sustained margin recovery or higher volumes to restore historic profitability levels over multiple quarters.
Rising Leverage And Weaker Equity BaseHigher leverage and a shrinking equity base reduce financial flexibility and amplify downside risk from cyclical hospital capex timing. Increased interest and covenant sensitivity can constrain strategic choices (M&A, R&D spend) and make the company more vulnerable if cash flows weaken again.
Persistent FX And Tariff HeadwindsSustained currency and tariff pressures materially depress reported sales and margins independent of underlying demand. Such external, structural volatility complicates multi‑period planning, reduces the payoff from cost programs, and can keep reported profitability muted even as operational execution improves.
Elekta AB News
EKTAY FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.42 and its highest was $6.88 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is $1.87B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Aug 27, 2026 which is in 62 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on May 28, 2026. The company reported -$0.246 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.246.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB pays a Semiannually dividend of $0.13 which represents an annual dividend yield of 0.21%. See more information on Elekta AB dividends here
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of -$0.246 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.986%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in EKTAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elekta AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EKTAY Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.41%
12-Months-Change
Fundamentals
Return on Equity
-6.37%
Trailing 12-Months
Asset Growth
-5.57%
Trailing 12-Months
Company Description
Elekta AB
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multidisciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.
EKTAY Company Deck
EKTAY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: clear commercial and operational positives (product approvals and launches, China recovery, improved gross margin and strong cash EBIT momentum, healthy book-to-bill and YTD cash flow improvement) alongside meaningful near-term headwinds (large FX and tariff impacts, a SEK 417m restructuring charge with further P&L effects, Americas revenue decline and some regional slowdowns). Management reiterated guidance, outlined structural cost savings (>SEK 500m run-rate) and emphasized execution of a new operating model. Given the mix of encouraging execution/operational improvements and significant external and one-time pressures, the tone is constructive but cautious.View all EKTAY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---